Clinical trials: COVID-19 Respiratory Infection
SARS-CoV-2 Infection
Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
This Phase 2/3 study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP has an acceptable immunogenicity and safety profile.
- Trial name
- NCT04636697
- Testing
- Intramuscular injection, Intramuscular vaccine
- Where
- 91 sites in United States, Argentina and 4 more
- Volunteers
- 30,918 people, healthy volunteers welcome
- Sponsor
- Medicago
COVID-19
A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19
This Phase Ⅱ/Ⅲ study is to evaluate whether or not there is a difference in time recovery of COVID-19 signs and symptoms through Day 29 between SIM0417/ritonavir and placebo.
- Trial name
- NCT05506176
- Testing
- SIM0417
- Where
- 35 sites in China
- Volunteers
- 1,208 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
COVID-19, SARS-CoV2 Infection
COVAG - Covid-19 Antigen Study - the Diagnostic Efficacy of SARS-CoV-2 Rapid Detection Tests
The aim of the COVAG study (Covid-19 Antigen study) is to assess the diagnostic efficacy of two of the most used rapid antigen tests (Roche \& Abbott).
- Conditions
- COVID-19, SARS-CoV2 Infection, SARS (Disease)
- Trial name
- COVAG (NCT05074017)
- Testing
- 3 nasopharyngeal swab
- Where
- 2 sites in Germany
- Volunteers
- 2,222 people, healthy volunteers welcome
- Sponsor
- Synlab Holding Deutschland GmbH
Covid19
A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults
The proposed trial will obtain preliminary data on the feasibility of studying RTB101 as compared to placebo for COVID-19 post-exposure prophylaxis in adults age ≥ 65 years to inform the design of a subsequent pivotal trial.
- Trial name
- NCT04584710
- Testing
- RTB101
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Restorbio Inc.
Long COVID
Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19
The Primary objective of this study is to determine, using unblinded samples, if it is possible to develop an algorithm for the classification of specific blood RNA from patients with long COVID together and separately from the…
- Trial name
- NCT06311435
- Testing
- RNA Biomarker Blood Test
- Where
- 3 sites in United States
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- MaxWell Clinic, PLC
Coronavirus, Respiratory Infection
Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses
The Biomedical Advanced Research and Development Authority (BARDA) has contracted BioFire Defense (BFDf) to develop the BioFire Emerging Coronavirus (ECoV) Panel, a nucleic acid test capable of detecting coronaviruses from…
- Conditions
- Coronavirus, Respiratory Infection, COVID
- Trial name
- NCT07221097
- Testing
- Investigational IVD for coronaviruses
- Where
- 6 sites in United States
- Volunteers
- 2,091 people
- Sponsor
- BioFire Defense LLC
Coronavirus Disease 2019 (COVID-19), Acute Lung Injury
Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
This was a randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the safety and efficacy of dociparstat sodium in adult patients with acute lung injury (ALI) due to Coronavirus Disease 2019 (COVID-19).
- Conditions
- Coronavirus Disease 2019 (COVID-19), Acute Lung Injury, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- Trial name
- NCT04389840
- Testing
- Dociparstat sodium
- Where
- 12 sites in United States
- Volunteers
- 27 people
- Sponsor
- Jazz Pharmaceuticals
Covid19
Post Acute COVID-19 Quality of Life (PAC-19QoL) Tool Development and Patient Registry (PAC-19QoLReg)
Coronavirus Disease 2019 (COVID-19) is a newly emerged disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT04586413
- Testing
- No intervention - quality of life measure
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Medialis Ltd.
Covid19
A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers
This is a single-centre, open-label, first-in-human, single ascending dose and multiple dose study to assess the safety, reactogenicity, and immunogenicity of the SC-Ad6-1 investigational product when administered via the…
- Trial name
- NCT04839042
- Testing
- SC-Ad6-1
- Where
- Australia
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Moat Biotechnology Corporation
COVID-19
JINZHEN for Treatment of Mild to Moderate COVID-19
JINZHEN is a botanical drug that contains eight chemical constituents extracted from plant, mineral and animal origin raw materials.
- Trial name
- NCT05092503
- Testing
- JINZHEN Granules for Oral Solution
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Lianyungang Kanion Group, Ltd.
SARS CoV 2 Infection
Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.
The objective of the study is to evaluate the efficacy and safety of two different doses of raloxifene orally administered compared to placebo in patients with early diagnosis of paucisymptomatic COVID-19.
- Trial name
- NCT05172050
- Testing
- Raloxifene
- Where
- 11 sites in France, Italy and 1 more
- Volunteers
- 61 people
- Sponsor
- Dompé Farmaceutici S.p.A
COVID-19
Efficacy of KOVIR Capsule in the Combination Regimen With Background Treatment in COVID-19 Patients
The acute pneumonia pandemic caused by a new strain of corona virus 2019, namely as COVID-19 by the World Health Organization (WHO), is a pandemic caused by SARS-CoV-2 virus.
- Trial name
- NCT05044650
- Testing
- KOVIR capsule combined with background treatment
- Where
- Vietnam
- Volunteers
- 1,000 people
- Sponsor
- Sao Thai Duong Joint Stock Company
Fever, Pneumonia
COVID-19 Epidemic Response Study
A national, observational, longitudinal, non-interventional program aiming to identify prognostic parameters, to investigate the kinetics of the immune response, and to identify predictive biomarkers in SARS-CoV-2 infected…
- Conditions
- Fever, Pneumonia, Cough
- Trial name
- COVeR (NCT04357496)
- Sponsor
- CENTOGENE GmbH Rostock
COVID-19
Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and Above
This trial adopts a randomized, double-blind and positive control design, it is planned to recruit 1800 healthy participants who have been vaccinated with 2/3 doses of COVID-19 inactivated vaccine or mRNA vaccine for 3 months.
- Trial name
- COVID-19 (NCT05382871)
- Testing
- BIBP Omicron Inactivated COVID-19 vaccine (Vero Cell), WIBP Omicron Inactivated COVID-19 vaccine (Vero Cell), COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- Hong Kong
- Volunteers
- 1,804 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
COVID-19 Pandemic
Oral Neutralizing Antibody Booster for Post-vaccinated People With COVID19 Vaccine
This is a study trial to assess the effectiveness of the immune response stimulated by the genetically engineered Bacillus subtilis spore extract which contain Spike protein of the SARS-COV2 on the spore coat.
- Trial name
- NCT05158855
- Testing
- Bacillus subtilis spore extract
- Where
- Macau
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- DreamTec Research Limited
SARS-CoV-2 (COVID-19) Infection
Safety, Tolerability, and Systemic Exposure of Apo-Si- K170A-C76 in Healthy Volunteers
The goal of this First in Human Phase 1 clinical trial is to to assess the safety, tolerability, and systemic exposure of single, twice daily (BID) doses and repeated BID doses of ascending dosing by intranasal administration of…
- Trial name
- BID (NCT07095049)
- Testing
- Apo-Si-K170A-C76
- Where
- Israel
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Interna Therapeutics Ltd.
COVID-19
A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)
This Phase III study is a global multicenter, randomized, double-blind,placebo controlled clinical trial to evaluate the efficacy, safety, and immunogenicity of therecombinant COVID-19 vaccine (Sf9 cells) in 40,000 participants…
- Trial name
- NCT04904471
- Testing
- Recombinant COVID-19 vaccine (Sf9 cells)
- Where
- 24 sites in Indonesia, Kenya and 3 more
- Volunteers
- 39,663 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
COVID-19
Effectiveness of Chinese COVID-19 Vaccines in Latin America and the Caribbean
This multi-country study seeks to collect real-world evidence (RWE), from Latin American and Caribbean countries, on the effectiveness of China-made COVID-19 vaccines in different populations, against different clinical outcomes…
- Trial name
- NCT05475704
- Where
- 5 sites in Argentina, Colombia and 2 more
- Volunteers
- 59 people
- Sponsor
- P95
COVID19, ARDS
REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia
To assess the safety and efficacy of CK0802 in treatment of patients with COVID-19 induced moderate-to-severe PNA-ARDS.
- Trial name
- RESOLVE (NCT04468971)
- Testing
- CK0802
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Cellenkos, Inc.
Cytokine Release Syndrome in COVID-19-induced Pneumonia
Canakinumab MAP in COVID-19 Pneumonia With CRS
This is a global Managed Access Program (MAP) to provide access to canakinumab to patients with cytokine release syndrome resulting from COVID-19 pneumonia
- Trial name
- NCT04476706
- Testing
- canakinumab
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.